MON, JUNE 14TH, 2021 08:00 CET

RLS Global clinical study, ChloraSolv01, published in the Journal of Wound Care

RLS Global is pleased to announce that the outcome of the completed clinical study ChloraSolv01 is published today in the Journal of Wound Care Vol 30, No 6, June 2021. Data from this clinical study show that a treatment regimen based on ChloraSolv could represent a valuable treatment option for patients suffering from hard-to-heal wounds.

The wounds that were treated in the ChloraSolv01 clinical study were hard-to-heal, lower extremity ulcers which had more than 50% coverage of devitalized tissue. Using ChloraSolv once a week for 5 weeks resulted in a 73% reduction of the devitalized tissue and the reduction of wound size during the study period shows that ChloraSolv does not negatively affect the natural healing process. The treatment was generally well tolerated, and patients reported a low pain score during the treatments. It is also shown that the treatment was perceived as positive and easy to handle both from the perspective of care recipients and caregivers.

“I am very pleased that the Journal of Wound Care, a highly respected industry journal, has published the results of our Chlorasolv01 clinical study, which increases the awareness of the potential benefits that ChloraSolv can bring the patients with hard-to-heal wounds”, says Karin Fischer, CEO, RLS Global. “Furthermore, through the successful outcome of this clinical study, ChloraSolv has been granted a new indication, leg ulcers.”

ChloraSolv has proved to be effective for the debridement and management of diabetic foot ulcers and leg ulcers. RLS will continue to collect evidence in clinical studies that this effect also can be shown for other hard-to-heal wounds.

The full article can be read in the latest issue of Journal of Wound Care. At the ChloraSolv homepage you can find a reprint of the article for download.

RLS long term vision is to be a leading research driven platform company in wound care. The ambition is to expand into new indications through new research and development project in areas such as burns and dermatology. In order to maximize our patient reach, RLS intends to work with partners to commercialize its products globally. RLS is confident in the company’s platform technology and its unique features and what this can bring to patients around the world.

RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email:
During the period 2012–2017, the company was listed on Aktietorget.

Karin Fischer, CEO
Telephone: +46 702-48 46 51

Mats Ahlenius, CTO
Telephone: +46 707 41 03 39


About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company’s unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North with Redeye Aktiebolag, phone: +46 8 121 576 90, email: Read more at